Physician profile
Xinlu Liu
NPI 1831553502
$3,850.44
in general payments reported to CMS, 2019-2025
24 companies · $750 in 2025
The $750 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.34 · 2020: $148 · 2021: $565 · 2022: $691 · 2023: $919 · 2024: $703 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,372.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $608.54 | 2021-2025 | |
| Novo Nordisk INC | $597.82 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $407.27 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $384.66 | 2020-2025 | Airsupra, Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $277.24 | 2022-2024 | |
| Lilly USA, LLC | $247.01 | 2022-2024 | Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $240.65 | 2021 | |
| Abbott Laboratories | $209.14 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $154.83 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $152.09 | 2022 | |
| Glaxosmithkline, LLC. | $100.57 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $91.30 | 2023 | Sunosi |
| Sumitomo Pharma America, INC. | $52.35 | 2025 | Gemtesa |
| Inari Medical, INC. | $51.90 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Exact Sciences Corporation | $47.19 | 2023-2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.46 | 2025 | Krystexxa, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $33.56 | 2022-2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.49 | 2024-2025 | Jardiance |
| Cequr Corporation | $28.29 | 2024 | Cequr Simplicity |
| Daiichi Sankyo INC. | $22.30 | 2025 | Injectafer |
| Corcept Therapeutics | $21.08 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $15.35 | 2023 | Keveyis |
| E.R. Squibb & Sons, L.L.C. | $15.15 | 2023 | Eliquis |
| Impel Pharmaceuticals INC. | $13.20 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xinlu Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.